◆ 会议时间：2025年1月30日-2月3日
◆ 会议地点：美国 拉斯维加斯

◆ 会议简介：

2025年美国介入肿瘤学会(SIO)年会将于2025年1月30日至2月3日在美国内华达州拉斯维加斯举行。SIO年度科学会议是一个旨在建立、培育和支持介入肿瘤学（IO）发展的科学论坛，介入治疗是指运用成像技术以精准定位和微创或无创的方式诊断和治疗局部癌症。会议结合了最高水准的讲座、小组讨论、特邀论文以及精选的基础、转化和临床研究的摘要，以促进就放射学、内科肿瘤学、外科肿瘤学、介入肿瘤学、肝病学和放射肿瘤学等领域的现有和新兴疗法进行有意义的对话。

介入肿瘤学会(SIO)由WCIO理事会于2017年1月成立，是一个支持和促进介入肿瘤学（IO）领域发展的非营利性协会。WCIO现在被称为SIO年度科学会议-宣译；SIO年会(原WCIO-世界肿瘤介入大会)是一个提供有关医疗技术以及如何在肿瘤实践中实施新技术的多学科峰会，提供多学科的癌症治疗方法，汇集了来自世界各地肿瘤介入治疗领域的专家、学者、医生，为介入、放射、超声、影像、肿瘤微创外科等相关科室的专家、临床医生、技师、护士以及从事肿瘤介入学研究的科研人员提供了解国际IO领域最新动态和学术交流的机会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

SIO 2025 - Society of Interventional Oncology (SIO) Annual Scientific Meeting

Dates: 30 January - 3 February 2025
Venue: Las Vegas, Nevada, USA

The SIO Annual Scientific Meeting offers sessions on medical technology and how to implement new technology in oncologic practice. The conference provides a multi-disciplinary approach to cancer care. The annual meeting brings together international health care providers for international sharing of ideas.

The conference leverages a combination of state-of-the-art lectures, panel discussions, invited papers, & selected abstracts of basic, translational, & clinical research to promote meaningful dialogue.

摘要征文投稿：

点此提交摘要>>>Submit Abstract>>>

Submission Guidelines

The abstract character limit is 4,000 with a minimum requirement of 50 characters. Please ensure that your submission is indicative of significant scientific work, a major update, and/or significant follow-up on established procedures and/or research. All abstract submissions are required to contain the following information for consideration and review:

• Abstract Title
• Purpose
• Materials and Methods
• Results
• Conclusions

Presentation Types

Oral

Abstracts submitted and accepted as this type will be presented by the presenting author during one of the two plenary afternoon oral abstract sessions.

E-Posters

Abstracts submitted and accepted as this type will be displayed on as virtual e-posters at the 2025 Annual Scientific Meeting in Las Vegas, Nevada. Accepted e-posters will not have dedicated presentation times, rather authors are encouraged to showcase their e-posters throughout the meeting during dedicated hours throughout the conference.

Categories

• Basic/Translational Science
• Chest and Thoracic
• Education
• Equity, Access, and Ethics
• Genitourinary
• HCC
• Imaging
• Industry1
• Liver Metastases
• Musculoskeletal
• Pain/Palliation
• Technology
• Trials in Progress2
• Other

1This category is reserved for industry-developed research and/or updates submitted by corporate entities. These abstracts will be considered separately from research developed by primary investigators and academic teams.

2See below for guidelines and policies regarding the submission of a “Trial in Progress” Abstract Submission

Abstract Policies and Procedures

Trials in Progress Policy

The Trials in Progress Category provides a unique opportunity for researchers to present ongoing trials at the SIO Annual Scientific Meeting.

Any phase (I, II, or III) trial that is ongoing, started enrolling patients or has completely enrolled, and has not yet reached prespecified endpoints for analysis may be considered for inclusion in the Trials in Progress submission category. Inclusion of results would be at the discretion of investigators. Presentation of preliminary results is not required for submission or acceptance.

All submissions will be reviewed for appropriateness by the SIO Annual Scientific Meeting Planning Committee. Accepted submissions will be notified of their presentation type.

Abstract Submissions for Trials in Progress should include Background, Methods, and Preliminary Results (optional, not required for acceptance):

Background:

• Scientific background/rationale for the trial
• Correlative studies of particular interest

Methods:

• Trial design and statistical methods
• Treatment or intervention planned
• Major eligibility criteria
• Clinical trial registration number (required)
• Enrollment status

Preliminary Results (not required for acceptance):

• Demographic, safety, and preliminary efficacy data (if appropriate for presentation).

What is not permissible in a Trials in Progress Abstract Submission:

• Proprietary drug name
• Information about pricing, fees, or reimbursement related to trial participation

Prior Presentation/Publication Abstract Submission Policy

SIO does not restrict the submission of abstracts that have been presented at prior meetings, or published prior to the 2025 Annual Scientific Meeting. If your submission has been presented prior to the 2025 Annual Scientific Meeting, please ensure you are adhering to the policies and procedures of the respective organization. SIO reserves the right to assign priority scoring to debut abstract presentations.

Embargo Policy and Information

All 2025 Annual Scientific Meeting Abstracts will be made public at the start of the conference, Thursday, 29 January 2025 at 7:00 am PST. Once an abstract has been made public, you may distribute a press release. SIO reserves the right to distribute press releases in advance of the release date above regarding submitted and accepted notable research.

Resubmission Policy for SIO Abstracts to Other Meetings

The process by which SIO Abstracts are submitted to other meetings is governed by the other meeting organizer. SIO does not prohibit the submission of previously accepted abstracts to other meetings however, it is strongly encouraged that submitting authors notify meeting organizers of their previous acceptance/presentation to SIO meetings.

Late-Breaking Abstracts

The SIO late-breaking abstract policy allows for the submission of late-breaking data and research which must contain information with results that were not yet discovered or available on the regular abstract submission deadline of 2 October 2024. Submissions for late-breaking abstracts will be announced following the regular abstract submission deadline on 14 January 2025.

Notification regarding late-breaking abstract’s acceptance or rejection will be sent to the submitter by 17 January 2025. Late-breaking abstracts should contain new information, which may include either:

• Results which were not fully known or available on the regular submission deadline
• Work that has been submitted for publication

Withdrawals and No-Show Policy

Acceptance of an abstract for any oral presentation obligates the author to attend the 2025 Annual Scientific Meeting to present in person. If circumstances prevent the presenting author’s attendance, the author must arrange for the work to be presented by a substitute, preferably a co-author. If you wish to withdraw your abstract, you must submit your request in writing by Tuesday, 7 January 2025 to education@sio-central.org and include the abstract title and presenting author’s name.

On rare occasions, selected presenters fail to show up without notifying the Society of Interventional Oncology. When presenters do not attend as planned, the efforts of the Scientific Chair and Program Committee to provide a quality program are diminished, significant costs are imposed, and the audience is unnecessarily disappointed. SIO staff will audit abstracts for no-shows. Failure to comply with these policies may result in ineligibility for participation in future SIO meetings.

SIO2025 注册费：

Full-Conference Registration

◆ 参会对象：临床医生/研究人员、放射科诊断医生、介入肿瘤学家和放射学家、外科医生、住院医师、医院管理者、医院科室主任/副主任、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。